26.25 +0.41 (1.49%)
VRX
Stock Details
Last Trade:26.25 Change:+0.41 (1.49%) Prev Close:25.84 Open: 27.55 Days Range:25.00 – 29.98 52 Week Range: 11.97 - 26.22 Volume:447773 P/E: N/AEPS:-2.15
View AllRecent Alerts 07/03/09
Recent Alert on 06/09/09 at 9:40am
Notable Analyst Rating Changes 6/9: X, CSX, OMTR, MRVL Higher; HIG, VRX, MAS Lower
Notable Analyst Rating Changes 6/9: X, CSX, OMTR, MRVL Higher; HIG, VRX, MAS Lower
UPGRADES: Morgan Stanley upgrades U.S. Steel (NYSE: X) from Equal-weight to Overweight. Goldman Sachs upgrades CSX Corp. (NYSE: CSX) from Neutral to Buy and raises their price target from $36 to $40. Morgan Stanley upgrades Omniture... Read More
Recent Alert on 06/09/09 at 8:38am
Penwest Pharma (PPCO, Endo Pharma (ENDP) Grant Valeant (VRX) Exclusive License to Market Opana(r) ER in Canada, Australia and New Zealand
Penwest Pharma (PPCO, Endo Pharma (ENDP) Grant Valeant (VRX) Exclusive License to Market Opana(r) ER in Canada, Australia and New Zealand
Recent Alert on 06/09/09 at 8:00am
Wachovia Downgrades Valeant Pharmaceuticals (VRX) to Underperform; Risk/Reward Unfavorable
Wachovia Downgrades Valeant Pharmaceuticals (VRX) to Underperform; Risk/Reward Unfavorable
Recent Alert on 06/01/09 at 9:25am
Valeant Pharmaceuticals (VRX) Reports Encouraging Final Results With Taribavirin Phase IIb Study
Valeant Pharmaceuticals (VRX) Reports Encouraging Final Results With Taribavirin Phase IIb Study
Recent Alert on 06/01/09 at 9:25am
Valeant Pharmaceuticals (VRX) Reports Encouraging Final Results With Taribavirin Phase IIb Study
Valeant Pharmaceuticals (VRX) Reports Encouraging Final Results With Taribavirin Phase IIb Study
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
SEC Filing on 07/01/09 at 8:23pm
Form 4 VALEANT PHARMACEUTICALS For: Jul 01 Filed by: KOPPES RICHARD
Form 4 VALEANT PHARMACEUTICALS For: Jul 01 Filed by: KOPPES RICHARD
View AllRecent Blog Posts
Blog Posts on 06/28/09 at 7:47am
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch